MedPath

MERCK KGAA

🇩🇪Germany
Ownership
Public
Established
1668-01-01
Employees
62.9K
Market Cap
$84.2B
Website
http://www.merckgroup.com/de

Clinical Trials

718

Active:427
Completed:245

Trial Phases

5 Phases

Phase 1:313
Phase 2:36
Phase 3:46
+2 more phases

Drug Approvals

12

NMPA:9
PHILIPPINES:3

Drug Approvals

Levothyroxine Sodium Tablets

Product Name
优甲乐
Approval Number
H20160060
Approval Date
Sep 25, 2019
NMPA

Levothyroxine Sodium Tablets

Product Name
优甲乐
Approval Number
H20160059
Approval Date
Sep 25, 2019
NMPA

Levothyroxine Sodium Tablets

Product Name
优甲乐
Approval Number
国药准字J20160066
Approval Date
Jul 31, 2019
NMPA

Levothyroxine Sodium Tablets

Product Name
优甲乐
Approval Number
国药准字J20160065
Approval Date
Jul 31, 2019
NMPA

Levothyroxine Sodium Tablets

Product Name
优甲乐
Approval Number
J20160065
Approval Date
Jul 31, 2019
NMPA

Levothyroxine Sodium Tablets

Product Name
优甲乐
Approval Number
J20160066
Approval Date
Jul 31, 2019
NMPA

Thiamazole Tablets

Product Name
赛治
Approval Number
J20171078
Approval Date
Nov 16, 2017
NMPA

Metformin Hydrochloride Extended-release Tablets

Product Name
格华止
Approval Number
J20171052
Approval Date
Sep 11, 2017
NMPA

Metformin Hydrochloride Extended-release Tablets

Product Name
格华止
Approval Number
国药准字J20171052
Approval Date
Sep 11, 2017
NMPA

Clinical Trials

Distribution across different clinical trial phases (444 trials with phase data)• Click on a phase to view related trials

Phase 1
313 (70.5%)
Phase 3
46 (10.4%)
Phase 4
46 (10.4%)
Phase 2
36 (8.1%)
Not Applicable
3 (0.7%)

Efficacy and Safety of Crinone Versus Combination Medication (ACCESS)

Phase 4
Terminated
Conditions
Infertility
Interventions
First Posted Date
2019-02-28
Last Posted Date
2024-03-12
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Target Recruit Count
172
Registration Number
NCT03858049
Locations
🇨🇳

Peking University Third Hospital, Beijing, China

L-PZQ ODT in Schistosoma Infected Children

Phase 3
Completed
Conditions
Schistosomiasis
Interventions
First Posted Date
2019-02-19
Last Posted Date
2024-03-21
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Target Recruit Count
288
Registration Number
NCT03845140
Locations
🇨🇮

Universitè de Cocody, Abidjan, Côte D'Ivoire

🇰🇪

Kemri Kisumu, Kisumu, Kenya

Effects of Cladribine Tablets on the PK of Microgynon®

Phase 1
Completed
Conditions
Relapsing Multiple Sclerosis (RMS)
Interventions
Drug: Microgynon®
Drug: Placebo
First Posted Date
2018-11-19
Last Posted Date
2024-03-15
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Target Recruit Count
28
Registration Number
NCT03745144
Locations
🇩🇪

St. Josef und St. Elisabeth Hospital gGmbH, Bochum, Germany

🇩🇪

Nuvisan GmbH, Neu-Ulm, Germany

🇵🇱

M.A. - LEK A.M.Maciejowscy SC., Katowice, Poland

and more 4 locations

Human Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Evobrutinib

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2018-10-30
Last Posted Date
2020-07-07
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Target Recruit Count
6
Registration Number
NCT03725072
Locations
🇳🇱

PRA Health Sciences, Groningen, Netherlands

Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC

Phase 2
Completed
Conditions
Squamous Non-Small Cell Lung Cancer
Interventions
First Posted Date
2018-10-24
Last Posted Date
2022-06-06
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Target Recruit Count
43
Registration Number
NCT03717155
Locations
🇭🇺

Semmelweis Egyetem - Pulmonologiai Klinika, Budapest, Hungary

🇭🇺

Debreceni Egyetem - Tudogyogyaszati Klinika, Debrecen, Hungary

🇭🇺

Petz Aladar Megyei Oktato Korhaz - Pulmonologiai Osztaly, Gyor, Hungary

and more 17 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 55
  • Next

News

Moffitt Cancer Center Reports Promising Results for Avelumab-Radiation Combination in Leptomeningeal Disease

Researchers at Moffitt Cancer Center demonstrated that combining avelumab immunotherapy with whole brain radiotherapy showed promising safety and efficacy in treating leptomeningeal disease, a devastating cancer complication.

Drug Hunter Secures Seed Investment to Expand Knowledge Platform for Pharmaceutical R&D

Drug Hunter, a knowledge platform serving over 200 pharmaceutical R&D organizations including Eli Lilly, Biogen, and NIH, announced seed funding led by Teamworthy Ventures to accelerate drug discovery insights.

NRG Therapeutics Raises $67 Million to Advance Novel Mitochondrial-Targeting Therapy for Parkinson's and ALS

NRG Therapeutics secured £50 million ($67 million) in Series B funding to advance its lead compound NRG5051 into clinical trials for Parkinson's disease and ALS.

Merck KGaA Appoints David Weinreich as Global Head of R&D to Revitalize Healthcare Pipeline

Merck KGaA has appointed David Weinreich as Global Head of R&D and Chief Medical Officer for its Healthcare business sector, bringing over 20 years of experience and leadership in developing 15 approved drugs worldwide.

Proxygen Partners with EPFL to Advance AI-Driven Molecular Glue Degrader Discovery

Proxygen, a leader in molecular glue degrader discovery, has announced a strategic research collaboration with EPFL to integrate AI-driven computational design with high-throughput screening platforms.

Rituximab Outperforms Cladribine in Real-World Multiple Sclerosis Study

A Norwegian observational study of 285 RRMS patients found rituximab demonstrated superior disease control compared to cladribine, with only 17% showing new MRI activity versus 57% for cladribine over 4 years.

Merck KGaA Partners with Skyhawk Therapeutics in $2 Billion RNA Splicing Collaboration for Neurological Disorders

Merck KGaA, Darmstadt, Germany has entered a strategic collaboration with Skyhawk Therapeutics valued at over $2 billion to discover novel RNA-targeting small molecules for neurological disorders with high unmet medical need.

RESTEM Receives FDA Orphan Drug Designation for Stem Cell Therapy in Polymyositis Treatment

RESTEM, a clinical-stage biotech company, received FDA Orphan Drug Designation in December 2024 for its umbilical cord outer lining stem cell program targeting polymyositis and dermatomyositis.

MilliporeSigma and Washington University Strengthen 90-Year Partnership to Accelerate Life Sciences Innovation

MilliporeSigma and Washington University in St. Louis have signed a memorandum of understanding to expand their nearly century-long collaboration, focusing on joint research initiatives and technology development.

Simtra BioPharma Solutions Completes Major Facility Expansion in Germany to Meet Growing Injectable Therapeutics Demand

Simtra BioPharma Solutions has completed construction of a new 1,800 square meter production facility at its Halle, Germany campus, expanding total production area to nearly 12,000 square meters.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.